Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

New licensing rules mandate compliance with Schedule TB for ASU nasal sprays for patient safety: Shardul Nautiyal, Mumbai Friday, January 24, 2025, 08:00 Hrs [IST] The Union minis ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Munson Healthcare is taking steps to make sure Narcan is accessible to everyone.It's partnering with Harm Reduction Michigan ...

Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material (CTM) requirements, ensuring ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The rink is set at the U.S. Figure Skating Championships in Wichita, Kansas — and the competition is already heating up!

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...